Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients?

Thrombosis Journal

Michel Vanhaeverbeek⁴  Yves Bouckaert⁵  Claude Remacle¹  Jean-Louis Vincent²  Philippe Cauchie⁴  Michel Guillaume³  Dany Brohée⁴  Michael Piagnerelli²  Karim Zouaoui Boudjeltia⁴ 

[1] Institute of life sciences, Laboratory of cellular Biology, Université Catholique de Louvain, Louvain-La-Neuve, Belgium;Dept of Intensive Care Medicine, Erasme Hospital, Free University of Brussels, Belgium;Dept of Cardiology, ISPPC, CHU A.Vésale, Montigny-Le-Tilleul, Belgium;Experimental Medicine Laboratory, ULB 222 Unit, ISPPC, CHU A. Vésale, Montigny-le-Tilleul, Belgium;Dept of Intensive Care Medicine, Tivoli Hospital, La Louvière, Belgium

关键词: endothelium dysfunction.;    sepsis;    inflammation;    euglobulin clot lysis time;    acute phase reactant;    C-reactive protein;   

Others  :  839915
DOI  :  10.1186/1477-9560-2-7

 received in 2004-08-11, accepted in 2004-09-30,  发布年份 2004

【 摘 要 】

Background-

Endothelial cell dysfunction may be implicated in the development of multiple organ failure (MOF) by a number of mechanisms. Among these, altered fibrinolysis promotes fibrin deposition, which may create microvascular alterations during inflammation. Elevated concentrations of C-reactive protein (CRP), especially when these persist over time, are correlated with an increased risk of MOF and death. CRP may inhibit fibrinolysis by inducing plasminogen activator inhibitor-1 (PAI-1) release from human aortic endothelial cells. Moreover, the administration of recombinant CRP in volunteers may increase circulating PAI-1 levels.

In this study, we tested the hypothesis that CRP is associated with hypofibrinolysis in intensive care patients with and without sepsis.

Methods-

We studied the association of inflammation and abnormal fibrinolysis in intensive care unit (ICU) patients with (n = 11) and without (n = 21) sepsis. The inflammatory response was assessed by serum concentration of C-reactive protein (CRP), a marker of the acute phase reaction, which increase rapidly in the inflammatory response, and the plasma fibrinolytic capacity was evaluated by the Euglobulin Clot Lysis Time (ECLT), determined by a new semi-automatic method.

Results-

ECLT was significantly higher in septic than non-septic patients (1104 ± 439 vs 665 ± 275 min; p = 0.002) and was significantly correlated with CRP concentration (R² = 0.45; p < 0.001). In a multivariate analysis, CRP was the strongest predictor of ECLT (R² = 0.51, F = 25.6, p < 0.001). In addition, the overall ICU length of stay was significantly correlated with CRP (R² = 0.264, p = 0.003) and ECLT (R² = 0.259, p = 0.003).

Conclusion-

In critically ill patients a significant correlation thus exists between plasma fibrinolytic capacity and serum CRP levels. Our data were obtained in the first 24 hours of ICU admission or of sepsis, thus, the relation between CRP and hypofibrinolysis appeared very quickly. This finding is compatible with a link between inflammation and abnormal fibrinolysis, and may explain the negative prognostic value of CRP in critically ill patients.

【 授权许可】

   
2004 Boudjeltia et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Levi M, ten Cate H, van der Poll T: Endothelium: interface between coagulation and inflammation. Crit Care Med 2002, 30:S220-S224.
• [2]Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765-3777.
• [3]Idell S: Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003, 31:S213-S220.
• [4]Gross PL, Aird WC: The endothelium and thrombosis. Semin Thromb Hemost 2000, 26:463-478.
• [5]Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL: C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003, 123:2043-2049.
• [6]Blann AD, Lip GY: Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003, 14:335-340.
• [7]Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105:1890-1896.
• [8]Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
• [9]Bisoendial RJ, Kasteleuin JJ, Levels JHM, Zwaginga JJ, Van den Bogaard B, Reitsma PH, Meijers CM, Hartman D, Levi M, Stroes ESG: Activation of inflammation and Coagulation after infusion of C-reactive protein in humans. Lancet, in press.
• [10]Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256.
• [11]Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D: A simplified acute physiologic score for ICU patients. Crit Care Med 1984, 12:975-977.
• [12]Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A: Relationship netween euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1. Thrombosis Haemostasis 1990, 63:82-86.
• [13]Boudjeltia KZ, Cauchie P, Remacle C, Guillaume M, Brohee D, Hubert JL, Vanhaeverbeek M: A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BMC Biotechnol 2002, 2:8. BioMed Central Full Text
• [14]Bombeli T, Mueller M, Haeberli A: Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997, 77:408-423.
• [15]Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000, 98:531-535.
• [16]Shah SH, Newby LK: C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 2003, 11:169-179.
• [17]Zouaoui Boudjeltia K, Guillaume M, Kinard F, Cauchie P, Remacle C, Ducobu J, Vanhaeverbeek M, Brohee D: Effect of blood monocyte counts on plasma fibrinolytic capacity. Atherosclerosis 2001, 2:83 (abstract).
• [18]Mesters RM, Florke N, Ostermann H, Kienast J: Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996, 75:902-907.
• [19]Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K: Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med 1999, 27:1814-1818.
• [20]Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992, 4:361-368.
• [21]Cao H, Hegele RA: Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet 2000, 45(2):100-1.
• [22]Szalai AJ, Briles DE, Volanakis JE: Human C-reactive protein is protective against fatal streptococcus pneumoniae infection in transgenic mice. The journal of immunology 1995, 155:2557-2563.
• [23]Szalai AJ, VanCott JL, McGhee JR, Volonakis JE, Benjamin WH: Human C-reactive protein is protective against fatal Salmonella enterica Serovar Typhimurium infection in Transgenic Mice. Infection and Immunity 2000, 68(10):5652-5656.